The
largest U.S. pharmacy chain's retail and long-term care segment
revenue rose 6.3%, helped by the sale of OTC test kits and the
impact of the flu season, which helped offset lower COVID-19
vaccinations and diagnostic testing.
Its insurance business reported an 11% growth in revenue as well
as a decrease in medical benefit ratio, which is the costs it
incurs as a percentage of premiums.
CVS raised its adjusted profit outlook to $8.40-$8.60 per share
from $8.20-$8.40 per share forecast earlier.
Net income for the quarter ended June 30 rose to $2.96 billion,
or $2.23 per share, from $2.79 billion, or $2.10 per share a
year earlier.
(By Leroy Leo and Bhanvi Satija in Bengaluru; Editing by Vinay
Dwivedi)
[© 2022 Thomson Reuters. All rights
reserved.]
This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.

|
|